Gilead Sciences
Stock Forecast, Prediction & Price Target
Gilead Sciences (GILD) stock Price Target by analysts
Gilead Sciences (GILD) stock Price Target by analysts
Average Price Target
$89.88
Potential downside: -23.57%
Gilead Sciences price prediction
What is Gilead Sciences stock analysts` prediction?
Gilead Sciences stock forecast: Based on 6 Wall Street analysts` predicted price targets for Gilead Sciences in the last 3 months, the avarage price target is $89.88, with a high forecast of $NaN. The average price target represents a -23.57% change from the last price of $117.6.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
Gilead Sciences stock Price Target by analysts
Full breakdown of analysts given Gilead Sciences price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
Joseph Catanzaro Piper Sandler | 0% 0/2 | 10 months ago | $105 -10.71% downside | $90.09 | StreetInsider | Previous targets (1) |
Andrew Berens Leerink Partners | 0% 0/1 | 10 months ago | $96 -18.36% downside | $86.72 | StreetInsider | Previous targets (0) |
Evan David Seigerman BMO Capital | 0% 0/3 | 10 months ago | $94 -20.06% downside | $86.11 | StreetInsider | Previous targets (2) |
Terence Flynn Morgan Stanley | 0% 0/2 | 11 months ago | $84 -28.57% downside | $87.07 | TheFly | Previous targets (1) |
Michael Yee Jefferies | 33.33% 1/3 | 11 months ago | $95 -19.21% downside | $83.76 | StreetInsider | Previous targets (2) |
Salveen Richter Goldman Sachs | 50% 1/2 | 12 months ago | $71 -39.62% downside | $82.85 | StreetInsider | Previous targets (1) |
Terence Flynn Morgan Stanley | 0% 0/2 | 12 months ago | $79 -32.82% downside | $82.63 | TheFly | Previous targets (1) |
Joseph Catanzaro Piper Sandler | 0% 0/2 | 12 months ago | $95 -19.21% downside | $79.93 | StreetInsider | Previous targets (1) |
Asthika Goonewardene Truist Financial | 0% 0/1 | about 1 year ago | $83 -29.42% downside | $74.14 | StreetInsider | Previous targets (0) |
Brian Abrahams RBC Capital | 25% 1/4 | about 1 year ago | $72 -38.77% downside | $75.59 | StreetInsider | Previous targets (3) |
Evan David Seigerman BMO Capital | 0% 0/3 | about 1 year ago | $85 -27.72% downside | $75.59 | StreetInsider | Previous targets (2) |
Steven Seedhouse Raymond James | 0% 0/1 | about 1 year ago | $93 -20.91% downside | $67.76 | StreetInsider | Previous targets (0) |
Michael Yee Jefferies | 33.33% 1/3 | about 1 year ago | $85 -27.72% downside | $71.24 | TheFly | Previous targets (2) |
Brian Skorney Robert W. Baird | 0% 0/1 | about 1 year ago | $80 -31.97% downside | $69.21 | StreetInsider | Previous targets (0) |
Salim Syed Mizuho Securities | 50% 1/2 | about 1 year ago | $90 -23.46% downside | $64.52 | StreetInsider | Previous targets (1) |
Brian Abrahams RBC Capital | 25% 1/4 | about 1 year ago | $74 -37.07% downside | $64.68 | StreetInsider | Previous targets (3) |
Evan David Seigerman BMO Capital | 0% 0/3 | over 1 year ago | $80 -31.97% downside | $67.9 | StreetInsider | Previous targets (2) |
Morten Herholdt HSBC | 0% 0/1 | over 1 year ago | $69 -41.32% downside | $67.08 | StreetInsider | Previous targets (0) |
Brian Abrahams RBC Capital | 25% 1/4 | over 1 year ago | $76 -35.37% downside | $73.53 | Benzinga | Previous targets (3) |
Brian Abrahams RBC Capital | 25% 1/4 | almost 2 years ago | $84 -28.57% downside | $75.9 | Benzinga | Previous targets (3) |
Geoff Meacham Bank of America Securities | 0% 0/1 | almost 2 years ago | $95 -19.21% downside | $75.92 | Benzinga | Previous targets (0) |
Unknown Leerink Partners | N/A | over 2 years ago | $91 -22.61% downside | $84.64 | Benzinga | N/A |
Unknown Piper Sandler | N/A | over 2 years ago | $112 -4.76% downside | $81.39 | Benzinga | N/A |
Unknown Wells Fargo | N/A | over 2 years ago | $90 -23.46% downside | $85.46 | Benzinga | N/A |
Unknown Morgan Stanley | N/A | over 2 years ago | $81 -31.12% downside | $88.34 | Benzinga | N/A |
Carter Gould Barclays | 100% 1/1 | almost 3 years ago | $76 -35.37% downside | $79.27 | TheFly | Previous targets (0) |
Robyn Karnauskas Truist Financial | 0% 0/1 | almost 3 years ago | $91 -22.61% downside | $70.2 | TheFly | Previous targets (0) |
Unknown Truist Financial | N/A | almost 3 years ago | $76 -35.37% downside | $64.82 | Benzinga | N/A |
Unknown Wells Fargo | N/A | almost 3 years ago | $74 -37.07% downside | $66.19 | Benzinga | N/A |
Evan Seigerman Loop Capital Markets | 100% 1/1 | about 3 years ago | $6.7 -94.30% downside | $59.54 | Investing | Previous targets (0) |
Unknown Morgan Stanley | N/A | about 3 years ago | $65 -44.72% downside | $62.3 | Benzinga | N/A |
David Risinger Leerink Partners | 100% 1/1 | over 3 years ago | $68 -42.17% downside | $64.04 | Pulse 2.0 | Previous targets (0) |
Do Kim Piper Sandler | 50% 1/2 | over 3 years ago | $69 -41.32% downside | $63.18 | Pulse 2.0 | Previous targets (1) |
Unknown Piper Sandler | N/A | over 3 years ago | $73 -37.92% downside | $60.04 | Benzinga | N/A |
Unknown BMO Capital | N/A | over 3 years ago | $63 -46.42% downside | $59.54 | Benzinga | N/A |
Do Kim Piper Sandler | 50% 1/2 | over 3 years ago | $71 -39.62% downside | $60.82 | Pulse 2.0 | Previous targets (1) |
Mohit Bansal Wells Fargo | 100% 1/1 | over 3 years ago | $63 -46.42% downside | $59.45 | Pulse 2.0 | Previous targets (0) |
Michael Yee Jefferies | 33.33% 1/3 | over 3 years ago | $80 -31.97% downside | $59.5 | TipRanks Contributor | Previous targets (2) |
Colin Bristow UBS | 100% 1/1 | over 3 years ago | $54 -54.08% downside | $59.85 | StreetInsider | Previous targets (0) |
Matthew Harrison Morgan Stanley | 100% 1/1 | over 3 years ago | $69 -41.32% downside | $59.85 | StreetInsider | Previous targets (0) |
Salim Syed Mizuho Securities | 50% 1/2 | over 3 years ago | $75 -36.22% downside | $63.7 | Pulse 2.0 | Previous targets (1) |
Steve Chesney Atlantic Equities | 100% 1/1 | over 3 years ago | $62 -47.27% downside | $63.1 | StreetInsider | Previous targets (0) |
Jason McCarthy Maxim Group | 100% 1/1 | over 3 years ago | $84 -28.57% downside | $64.57 | TheFly | Previous targets (0) |
Hartaj Singh Oppenheimer | 0% 0/1 | over 3 years ago | $90 -23.46% downside | $64.57 | StreetInsider | Previous targets (0) |
David Toung Argus Research | 100% 1/1 | over 3 years ago | $75 -36.22% downside | $67.99 | TheFly | Previous targets (0) |
Salveen Richter Goldman Sachs | 50% 1/2 | over 3 years ago | $80 -31.97% downside | $67.94 | TheFly | Previous targets (1) |
Robert Driscoll Wedbush | 100% 1/1 | almost 4 years ago | $67 -43.02% downside | $67.14 | StreetInsider | Previous targets (0) |
Cory Kasimov J.P. Morgan | 100% 1/1 | over 4 years ago | $74 -37.07% downside | $61.14 | TipRanks | Previous targets (0) |
Gilead Sciences Financial Estimates
Gilead Sciences Revenue Estimates
Gilead Sciences EBITDA Estimates
Gilead Sciences Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $27.30B N/A | $27.28B -0.08% | $27.11B -0.60% | Avg: $27.98B Low: $27.35B High: $28.64B avg. 3.20% | Avg: $28.74B Low: $28.12B High: $29.35B avg. 2.70% | Avg: $29.78B Low: $29.15B High: $30.42B avg. 3.63% | Avg: $31.05B Low: $30.38B High: $31.71B avg. 4.24% |
Net Income
% change YoY
| $6.22B N/A | $4.59B -26.23% | $5.66B 23.36% | Avg: $6.30B Low: $3.83B High: $7.90B avg. 11.30% | Avg: $6.83B Low: $3.84B High: $9.37B avg. 8.39% | Avg: $10.09B Low: $9.81B High: $10.37B avg. 47.69% | Avg: $10.77B Low: $10.47B High: $11.07B avg. 6.70% |
EBITDA
% change YoY
| $9.45B N/A | $10.39B 9.90% | $10.49B 0.99% | Avg: $9.94B Low: $9.72B High: $10.18B avg. -5.20% | Avg: $10.21B Low: $9.99B High: $10.43B avg. 2.70% | Avg: $10.59B Low: $10.36B High: $10.81B avg. 3.63% | Avg: $11.04B Low: $10.80B High: $11.27B avg. 4.24% |
EPS
% change YoY
| $4.96 N/A | $3.66 -26.20% | $4.54 24.04% | Avg: $5.17 Low: $3.05 High: $6.28 avg. 13.90% | Avg: $5.55 Low: $3.06 High: $7.45 avg. 7.34% | Avg: $8.02 Low: $7.8 High: $8.25 avg. 44.55% | Avg: $8.56 Low: $8.32 High: $8.8 avg. 6.70% |
Operating Expenses
% change YoY
| $10.60B N/A | $10.65B 0.38% | $13.01B 22.18% | Avg: $5.75B Low: $5.62B High: $5.88B avg. -55.81% | Avg: $5.90B Low: $5.77B High: $6.03B avg. 2.70% | Avg: $6.12B Low: $5.98B High: $6.25B avg. 3.63% | Avg: $6.38B Low: $6.24B High: $6.51B avg. 4.24% |
FAQ
What is Gilead Sciences stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 18.52% in 2025-2028.
We have gathered data from 19 analysts. Their low estimate is 3.83B, average is 6.30B and high is 7.90B.
What is Gilead Sciences stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 3.44% in 2025-2028.
We have gathered data from 21 analysts. Their low revenue estimate is $27.35B, average is $27.98B and high is $28.64B.
What is Gilead Sciences stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 18.12% in 2025-2028.
We have gathered data from 19 analysts. Their low earnings per share estimate is $3.05, average is $5.17 and high is $6.28.
What is the best performing analyst?
In the last twelve months 6 analysts have been covering Gilead Sciences stock. The most successful analyst is Joseph Catanzaro.